227 related articles for article (PubMed ID: 28446822)
1. Anti-Mycobacterium activity of microbial peptides in a silkworm infection model with Mycobacterium smegmatis.
Yagi A; Uchida R; Hamamoto H; Sekimizu K; Kimura KI; Tomoda H
J Antibiot (Tokyo); 2017 May; 70(5):685-690. PubMed ID: 28446822
[TBL] [Abstract][Full Text] [Related]
2. Development of an in vivo-mimic silkworm infection model with Mycobacterium avium complex.
Yagi A; Yamazaki H; Terahara T; Yang T; Hamamoto H; Imada C; Tomoda H; Uchida R
Drug Discov Ther; 2021 Jan; 14(6):287-295. PubMed ID: 33250497
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Anti-Mycobacterial Compounds in a Silkworm Infection Model with
Hosoda K; Koyama N; Hamamoto H; Yagi A; Uchida R; Kanamoto A; Tomoda H
Molecules; 2020 Oct; 25(21):. PubMed ID: 33121091
[TBL] [Abstract][Full Text] [Related]
4. In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria.
Kaur D; Khuller GK
Int J Antimicrob Agents; 2001 Jan; 17(1):51-5. PubMed ID: 11137649
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.
Altaf M; Miller CH; Bellows DS; O'Toole R
Tuberculosis (Edinb); 2010 Nov; 90(6):333-7. PubMed ID: 20933470
[TBL] [Abstract][Full Text] [Related]
6. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis.
Taneja NK; Tyagi JS
J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560
[TBL] [Abstract][Full Text] [Related]
7. A short-term model for preliminary screening of potential anti-tubercular compounds.
Jhamb SS; Singh PP
Scand J Infect Dis; 2009; 41(11-12):886-9. PubMed ID: 19922075
[TBL] [Abstract][Full Text] [Related]
8. Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound.
Garcia PK; Annamalai T; Wang W; Bell RS; Le D; Martin Pancorbo P; Sikandar S; Seddek A; Yu X; Sun D; Uhlemann AC; Tiwari PB; Leng F; Tse-Dinh YC
PLoS One; 2019; 14(2):e0207733. PubMed ID: 30794538
[TBL] [Abstract][Full Text] [Related]
9. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
Singh S; Roy KK; Khan SR; Kashyap VK; Sharma A; Jaiswal S; Sharma SK; Krishnan MY; Chaturvedi V; Lal J; Sinha S; Dasgupta A; Srivastava R; Saxena AK
Bioorg Med Chem; 2015 Feb; 23(4):742-52. PubMed ID: 25614114
[TBL] [Abstract][Full Text] [Related]
10. Structure and total synthesis of fungal calpinactam, a new antimycobacterial agent.
Koyama N; Kojima S; Fukuda T; Nagamitsu T; Yasuhara T; Omura S; Tomoda H
Org Lett; 2010 Feb; 12(3):432-5. PubMed ID: 20030344
[TBL] [Abstract][Full Text] [Related]
11. A novel screening method based on menadione mediated rapid reduction of tetrazolium salt for testing of anti-mycobacterial agents.
Singh U; Akhtar S; Mishra A; Sarkar D
J Microbiol Methods; 2011 Feb; 84(2):202-7. PubMed ID: 21129420
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and structural investigations on phosphoribosylpyrophosphate synthetase from Mycobacterium smegmatis.
Donini S; Garavaglia S; Ferraris DM; Miggiano R; Mori S; Shibayama K; Rizzi M
PLoS One; 2017; 12(4):e0175815. PubMed ID: 28419153
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.
Lu T; Drlica K
J Antimicrob Chemother; 2003 Dec; 52(6):1025-8. PubMed ID: 14613961
[TBL] [Abstract][Full Text] [Related]
15. Calpinactam, a new anti-mycobacterial agent, produced by Mortierella alpina FKI-4905.
Koyama N; Kojima S; Nonaka K; Masuma R; Matsumoto M; Omura S; Tomoda H
J Antibiot (Tokyo); 2010 Apr; 63(4):183-6. PubMed ID: 20186169
[TBL] [Abstract][Full Text] [Related]
16. Loperamide exerts a direct bactericidal effect against M. tuberculosis, M. bovis, M. terrae and M. smegmatis.
Barrientos OM; Juárez E; Gonzalez Y; Castro-Villeda DA; Torres M; Guzmán-Beltrán S
Lett Appl Microbiol; 2021 Mar; 72(3):351-356. PubMed ID: 33220096
[TBL] [Abstract][Full Text] [Related]
17. Drug susceptibility testing of mature Mycobacterium tuberculosis H37Ra and Mycobacterium smegmatis biofilms with calorimetry and laser spectroscopy.
Solokhina A; Bonkat G; Kulchavenya E; Braissant O
Tuberculosis (Edinb); 2018 Dec; 113():91-98. PubMed ID: 30514518
[TBL] [Abstract][Full Text] [Related]
18. Eagle Effect in Nonreplicating Persister Mycobacteria.
Wu ML; Tan J; Dick T
Antimicrob Agents Chemother; 2015 Dec; 59(12):7786-9. PubMed ID: 26349831
[TBL] [Abstract][Full Text] [Related]
19. Quantitative evaluation of Mycobacterium abscessus clinical isolate virulence using a silkworm infection model.
Matsumoto Y; Fukano H; Hasegawa N; Hoshino Y; Sugita T
PLoS One; 2022; 17(12):e0278773. PubMed ID: 36538550
[TBL] [Abstract][Full Text] [Related]
20. [Establishment and drug susceptibility test of isoniazid resistant Mycobacterium smegmatis].
Jia PP; Zhao LL; Li XY; Zhang Q; Liu ZL; Wang X; Yu LY; Zhao LX; Cen S
Yao Xue Xue Bao; 2011 Apr; 46(4):377-82. PubMed ID: 21751489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
